HOME
  Home > How to Use DEFINITY® > Administration Options > For IV Bolus Technique  

For IV Bolus Technique1

The IV Bolus method uses a weight-based dose of activated DEFINITY® followed by a preservative-free saline flush.

Bolus Injections

Supplies Needed

*If INTELLIPIN® is used, there is no need for 18-20 gauge needles.

Dosing

Guidelines for 10 μL/kg IV bolus injection of activated DEFINITY®.
Verify patient’s weight [kg] and total dose [mL] prior to injecting.

Example Weight Conversion to Kilograms
Weight conversion example
Example DEFINTY® Dose Calculation
Example Definity Dose Calculation

Weight Conversion to Kilograms

Weight conversion formula

DEFINITY® Dose Calculation
DEFINITY DOSE CALCULATION


Two Methods of Preparation

When withdrawing activated DEFINITY® from the vial it is important to use a venting method. Venting avoids negative pressure in the vial and allows for easier contrast withdrawal. Air should never be injected into the vial.

Venting with standard needle
This venting technique uses a second needle as an air vent which allows air to be drawn into the vial as the contrast is withdrawn into the syringe.

Venting with INTELLIPIN®

This technique eliminates the use of a second needle. A built in venting port allows air to flow into the vial as the contrast is being withdrawn into the syringe.

Administration

  1. DEFINITY package insert, April 2008, Lantheus Medical Imaging, Inc.

INDICATIONS

Activated DEFINITY® (Perflutren Lipid Microsphere) Injectable Suspension is indicated for use in patients with suboptimal echocardiograms to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border.

The safety and efficacy of DEFINITY® with exercise stress or pharmacologic stress testing have not been established.

CONTRAINDICATIONS

Do not administer DEFINITY® to patients with known or suspected right-to-left, bi-directional or transient right-to-left cardiac shunts, by intra-arterial injection, or to patients with known hypersensitivity to perflutren.

IMPORTANT SAFETY INFORMATION

WARNING: Serious Cardiopulmonary Reactions 

Serious cardiopulmonary reactions, including fatalities, have occurred during or following perflutren-containing microsphere administration.

  • Assess all patients for the presence of any condition that precludes DEFINITY® administration (see CONTRAINDICATIONS).
  • In patients with pulmonary hypertension or unstable cardiopulmonary conditions, monitor vital sign measurements, electrocardiography and cutaneous oxygen saturation during and for at least 30 minutes after DEFINITY® administration (see WARNINGS).
  • Always have resuscitation equipment and trained personnel readily available.


In post marketing use, rare but serious cardiopulmonary or anaphylactoid reactions have been reported during or shortly following perflutren-containing microsphere administration (see ADVERSE REACTIONS). The risk for these reactions may be increased among patients with pulmonary hypertension or unstable cardiopulmonary conditions. It is not always possible to reliably establish a causal relationship to drug exposure due to the presence of underlying cardiopulmonary disease.

Please See Full Prescribing Information and Letter to Healthcare Providers.